PORCILIS PARVO

Страна: Ірландія

мова: англійська

Джерело: HPRA (Health Products Regulatory Authority)

Активний інгредієнт:

INACTIVATED PORCINE PARVOVIRUS STRAIN 014

Доступна з:

Intervet Ireland Limited

Код атс:

QI09AA02

ІПН (Міжнародна Ім'я):

INACTIVATED PORCINE PARVOVIRUS STRAIN 014

Дозування:

Unknown

Фармацевтична форма:

Suspension for Injection

Тип рецепту:

LM-Licensed Merchant

Терапевтична група:

Porcine

Терапевтична области:

Porcine parvovirus vaccine

Терапевтичні свідчення:

Immunological - Inactivated vaccine

Статус Авторизація:

Authorised

Дата Авторизація:

2001-04-25

Характеристики продукта

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Porcilis Parvo
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
1 dose (2 ml) contains:
Active substance
Inacivated porcine parvovirus (PPV) strain 014
552 EU*
Adjuvant:
dl-
-tocopherol acetate
150 mg
Excipients:
Formaldehyde
1.08 mg
For a full list of excipients, see section 6.1.
*as determined in the final product antigenic mass ELISA
3 PHARMACEUTICAL FORM
Suspension for injection.
Nearly white liquid.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Sows and gilts
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the active immunisation of sows and gilts to prevent or reduce
mortality and clinical signs of porcine parvovirus
infection on embryos and foetuses during pregnancy.
4.3 CONTRAINDICATIONS
None.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Only healthy animal_S_ should be vaccinated.
After vaccination with Porcilis Parvo, animals may seroconvert and
detectable levels of antibody to PPV may persist.
PPV infection is not the only cause of reproductive failure in pigs.
A good immune response is reliant
on the reaction of an immunogenic agent
and a fully competent
immune system.
Immunogenicity
of
the
vaccine
antigen
will
be
reduced
by
poor
storage
or
inappropriate
administration.
Immunocompetence of the animal may be compromised by a variety of
factors including poor health, nutritional status,
genetic factors, concurrent drug therapy and stress.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_1_
_7_